Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


Blockbuster win for Novartis

Posted 14 October 2020

The patent on an oral form of the Novartis blockbuster multiple sclerosis drug Gilenya has been given the go ahead to proceed to grant after a ruling in the Federal Court ended a three year legal stoush with generic giant Arrow Pharmaceuticals.

"Novartis welcomes the decision by Justice Burley that the appeal be allowed and the patent application proceed to grant," the company said in a statement.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
How much to save the kid?
We paid a high price for our elderly so what about children
Special Report
Aust Covid Vaccine Tracker
UPDATES: Sanofi/GSK sign Statement of Intent with Gavi; Aust to import 3.8m vax doses
Approvals Action
Novartis' triplet inhaler ticked
First-in-class maintenance treatment of asthma